cmAngio® vs Viz AAA

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by CureMetrix
VS
by Viz.ai

AI Verdict

cmAngio® focuses on detecting Breast Arterial Calcifications on mammograms to assess long-term cardiovascular risk, primarily serving radiology and OB/GYN for preventative health. In contrast, Viz AAA is designed for the rapid detection and triage of acute Abdominal Aortic Aneurysms from CT angiography scans, optimizing emergency care coordination and vascular surgery workflows. While both utilize AI in medical imaging for cardiovascular insights, their distinct target conditions, imaging modalities, and clinical applications make them suitable for different clinical needs.

Choose cmAngio® if…

Choose cmAngio® if your primary goal is to leverage existing mammography screenings for proactive cardiovascular risk assessment in women. This tool is ideal for identifying Breast Arterial Calcifications (BAC) to provide early insights into potential cardiovascular health concerns without requiring additional patient procedures or radiation exposure. It integrates seamlessly into radiology workflows for comprehensive women's health evaluations.

View cmAngio® →

Choose Viz AAA if…

Choose Viz AAA if your priority is the rapid detection, triage, and coordinated management of suspected Abdominal Aortic Aneurysms (AAA) from CT angiography scans, especially in acute care settings. This solution is best suited for accelerating critical treatment decisions and improving patient outcomes by providing real-time alerts and facilitating communication among emergency medicine, radiology, and vascular surgery teams.

View Viz AAA →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature cmAngio® Viz AAA
Pricing Paid, out-of-pocket Enterprise (hospital/health system)
Deployment Cloud-based, integrates with any DICOM-compliant viewer Cloud-based, integrates with PACS and EHR systems.
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Viz AAA

While Tool A emphasizes quick installation and compatibility with existing DICOM viewers, Tool B offers a more comprehensive and integrated user experience. It provides real-time alerts, a HIPAA-compliant communication platform, and mobile access for care teams, streamlining workflow and decision-making across multiple specialists.

Clinical Value

Viz AAA

Both tools offer significant clinical value. However, Viz AAA (Tool B) addresses an acute, life-threatening condition (Abdominal Aortic Aneurysm) where rapid detection and accelerated care coordination can directly lead to life-saving interventions and improved patient outcomes. CmAngio (Tool A) provides valuable long-term cardiovascular risk assessment, but the immediate and critical impact on patient survival for AAA gives Viz AAA a stronger clinical value proposition.

Pricing & Value

cmAngio®

Both tools lack public pricing transparency, making a direct comparison difficult. However, Tool A explicitly mentions 'limited-time offers for no-cost implementation and service,' which could represent a significant initial value proposition for healthcare providers looking to adopt AI without substantial upfront investment. Tool B's subscription model, while common, does not offer similar publicly stated incentives.

Enterprise Readiness

Viz AAA

Both are FDA-cleared, HIPAA-compliant, and cloud-based, indicating a baseline of enterprise readiness. However, Tool B explicitly states it has a Business Associate Agreement (BAA) and is part of a broader 'Viz AORTIC Module,' suggesting a more mature and integrated enterprise offering with established infrastructure for comprehensive aortic pathology solutions. Viz.ai's extensive deployment across over 1700 hospitals further demonstrates its proven enterprise readiness and scalability.

Innovation

Viz AAA

While both are innovative, Tool B demonstrates a broader scope of innovation by combining AI detection with real-time care coordination, communication, and automated triage for an acute, time-sensitive condition. This integrated approach to accelerating the entire care pathway, rather than just providing a detection, represents a more comprehensive and impactful innovation in healthcare delivery.

Support & Docs

Viz AAA

Viz.ai (Tool B) clearly outlines robust support mechanisms, including 24/7 urgent phone support, a dedicated help center, customer resources, and a training app. In contrast, CureMetrix (Tool A) only provides a general 'Support' link on its website and mentions an operator's manual, indicating less transparent or comprehensive support offerings.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature cmAngio® Viz AAA
Name cmAngiou00ae Viz AAA
Primary Detection Target Breast Arterial Calcifications (BAC) Abdominal Aortic Aneurysm (AAA)
Imaging Modality Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams CT angiography scans
Key Feature: Workflow Integration/Alerts Compatible with any DICOM-compliant viewer; Quick and easy installation. Automated triage and prioritization of cases; Real-time alerts to care teams; Integration into existing hospital workflows; Mobile access.
Specialties Cardiology, Obstetrics & Gynecology, Radiology Emergency Medicine, Radiology, Vascular Surgery

Videos

Demos, reviews, and walkthroughs featuring cmAngio® and Viz AAA.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

cmAngiou00ae by CureMetrix is designed for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. Viz AAA by Viz.ai focuses on the detection and triage of suspected Abdominal Aortic Aneurysm (AAA) from CT angiography scans.
cmAngiou00ae processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams. Viz AAA utilizes CT angiography scans for the automatic detection of suspected AAA.
cmAngiou00ae provides visualization of BAC location on a scorecard and enables BAC identification and reporting without additional radiation or procedures. Viz AAA offers automated triage, real-time alerts to care teams, and a HIPAA-compliant communication platform for multidisciplinary teams, designed to accelerate treatment decisions and improve patient outcomes.
cmAngiou00ae is relevant for Cardiology, Obstetrics & Gynecology, and Radiology specialties. Viz AAA primarily serves Emergency Medicine, Radiology, and Vascular Surgery.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.